论文部分内容阅读
目的:测定ICAM-1在乳腺浸润性导管癌(IDC)中的表达情况,并探讨其在乳腺IDC进展中的意义。方法:应用免疫组织化学方法研究49例乳腺IDC标本中不同组织成分ICAM-1的表达情况,并统计分析其与淋巴结转移、组织学分级及TNM分期之间的关系。结果:ICAM-1在乳腺IDC癌巢中的表达强度明显低于癌旁正常乳腺导管上皮(P<0.05)及癌间质成分(P<0.05),ICAM-1在乳腺IDC癌巢中的表达阳性率亦明显低于正常乳腺导管上皮(P<0.05)。ICAM-1在乳腺IDC癌巢中的表达阳性率与淋巴结转移呈负相关(rs=-0.312,P<0.05),而与组织学分级及TNM分期无关。结论:ICAM-1的表达水平在乳腺IDC癌巢中与癌旁正常乳腺导管上皮中明显不同,ICAM-1在乳腺IDC中的表达缺失或下调可能更易于肿瘤的淋巴结转移。对ICAM-1的作用机制的深入研究有可能使其成为乳腺IDC患者个体化治疗的新靶点。
OBJECTIVE: To determine the expression of ICAM-1 in breast invasive ductal carcinoma (IDC) and to explore its significance in the progression of breast IDC. Methods: Immunohistochemistry was used to study the expression of ICAM-1 in different tissues of 49 cases of breast IDC specimens. The relationship between ICAM-1 expression and lymph node metastasis, histological grade and TNM stage were analyzed statistically. Results: The expression intensity of ICAM-1 in breast cancer IDC was significantly lower than that in adjacent normal breast tissue (P <0.05) and cancer stroma (P <0.05). The expression of ICAM-1 in breast cancer IDC The positive rate was also significantly lower than that of normal ductal epithelium (P <0.05). The positive rate of ICAM-1 expression in breast cancer IDC was negatively correlated with lymph node metastasis (rs = -0.312, P <0.05), but not with histological grade and TNM stage. Conclusion: The expression level of ICAM-1 in breast cancer IDC is significantly different from that in adjacent normal breast ductal epithelium. The loss or down-regulation of ICAM-1 expression in breast IDC may be more susceptible to tumor lymph node metastasis. In-depth study of the mechanism of ICAM-1 may make it a new target for individualized treatment of breast IDC patients.